Genetics and natural history of multiple sclerosis

Seminars in Neurology

Volumn 28, Issue 1, 2008, Pages 7-16

  Kantarci, Orhun H ^a  

^a Mayo Clinic   (United States)

Author keywords

Genetic epidemiology; Multiple sclerosis; Natural history; Prognosis

Indexed keywords

APOLIPOPROTEIN E; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GAMMA INTERFERON; HLA DR ANTIGEN; INTERLEUKIN 7 RECEPTOR;

DEMYELINATING DISEASE; DISEASE COURSE; DISEASE SEVERITY; DNA POLYMORPHISM; GENETIC ASSOCIATION; GENETIC EPIDEMIOLOGY; GENETIC LINKAGE; GENETIC SUSCEPTIBILITY; HUMAN; IDIOPATHIC DISEASE; INHERITANCE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PHENOTYPE; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; RISK FACTOR; SURVIVAL;

DEMYELINATING DISEASES; DISEASE PROGRESSION; HUMANS; MULTIPLE SCLEROSIS; SURVIVAL; TREATMENT OUTCOME;

EID: 39449090773     PISSN: 02718235     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-1019125     Document Type: Review

References (102)

1. Lucchinetti CF, Parisi J, Bruck W. The pathology of multiple sclerosis. Neurol Clin 2005;23(1):77-105
2. Kantarci OH, Weinshenker BG. Natural history of multiple sclerosis. Neurol Clin 2005;23(1):17-38
3. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001;50(1):121-127
4. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13(3):227-231
5. Kantarci OH, de Andrade M, Weinshenker BG. Identifying disease modifying genes in multiple sclerosis. J Neuroimmunol 2002;123(1-2):144-159
6. Oksenberg JR, Barcellos LF. The complex genetic aetiology of multiple sclerosis. J Neurovirol 2000;6(S2):S10-S14
7. Ebers GC, Sadovnick AD, Risch NJ. A genetic basis for familial aggregation in multiple sclerosis. Canadian Collaborative Study Group [see comment]. Nature 1995;377(6545):150-151
8. Weinshenker BG. Epidemiology of multiple sclerosis. Neurol Clin 1996;14(2):291-308
9. Ebers GC. A twin consensus in MS [see comment]. Mult Scler 2005;11(5):497-499
10. Kantarci OH, Barcellos LF, Atkinson EJ, et al. Men transmit MS more often to their children vs women: the Carter effect. Neurology 2006;67(2):305-310
11. Ebers GC, Sadovnick AD, Dyment DA, et al. Parent-of-origin effect in multiple sclerosis: observations in half-siblings. Lancet 2004;363(9423):1773- 1774
12. Herrera BM, Ramagopalan SV, Orton S, et al. Parental transmission of MS in a population-based Canadian cohort [see comment]. Neurology 2007;69(12):1208-1212
13. Hensiek AE, Seaman SR, Barcellos LF, et al. Familial effects on the clinical course of multiple sclerosis. Neurology 2007;68(5):376-383
14. Weiss KM, Terwilliger JD. How many diseases does it take to map a gene with SNPs? Nat Genet 2000;26(2):151-157
15. GAMES; Transatlantic Multiple Sclerosis Genetics Cooperative. A meta-analysis of whole genome linkage screens in multiple sclerosis. J Neuroimmunol 2003;143(1-2):39-46
16. Sawcer S, Compston A. The genetic analysis of multiple sclerosis in Europeans: concepts and design [see comment]. J Neuroimmunol 2003;143(1-2):13-16
17. Sawcer S, Ban M, Maranian M, et al. A high-density screen for linkage in multiple sclerosis. Am J Hum Genet 2005;77:454-467
18. Oksenberg JR, Barcellos LF, Cree BA, et al. Mapping multiple sclerosis susceptibility to the HLA-DR locus in African Americans. Am J Hum Genet 2004;74(1):160-167
19. Lincoln MR, Montpetit A, Cader MZ, et al. A predominant role for the HLA class II region in the association of the MHC region with multiple sclerosis. Nat Genet 2005;37(10):1108-1112
20. Barcellos LF, Sawcer S, Ramsay PP, et al. Heterogeneity at the HLA-DRB1 locus and risk for multiple sclerosis. Hum Mol Genet 2006;15(18):2813-2824
21. Reich D, Patterson N, De Jager PL, et al. A whole-genome admixture scan finds a candidate locus for multiple sclerosis susceptibility. Nat Genet 2005;37(10):1113-1118
22. Gough SC, Walker LS, Sansom DM. CTLA4 gene polymorphism and autoimmunity. Immunol Rev 2005;204:102-115
23. Harbo HF, Celius EG, Vartdal F, Spurkland A. CTLA4 promoter and exon 1 dimorphisms in multiple sclerosis. Tissue Antigens 1999;53(1):106-110
24. Ligers A, Xu C, Saarinen S, Hillert J, Olerup O. The CTLA-4 gene is associated with multiple sclerosis. J Neuroimmunol 1999;97(1-2):182-190
25. Fukazawa T, Yanagawa T, Kikuchi S, et al. CTLA-4 gene polymorphism may modulate disease in Japanese multiple sclerosis patients. J Neurol Sci 1999;171(1):49-55
26. Kantarci OH, Hebrink DD, Achenbach SJ, et al. CTLA4 is associated with susceptibility to multiple sclerosis. J Neuroimmunol 2003;134(1-2):133-141
27. Suppiah V, Alloza I, Heggarty S, et al. The CTLA4 + 49 A/G*G-CT60*G haplotype is associated with susceptibility to multiple sclerosis in Flanders. J Neuroimmunol 2005;164(1-2):148-153
28. Dincic E, Zivkovic M, Stankovic A, et al. Association of polymorphisms in CTLA-4, IL-1ra and IL-1beta genes with multiple sclerosis in Serbian population. J Neuroimmunol 2006;177(1-2):146-150
29. Malferrari G, Stella A, Monferini E, et al. Ctla4 and multiple sclerosis in the Italian population. Exp Mol Pathol 2005;78(1):55-57
30. Alizadeh M, Babron MC, Birebent B, et al. Genetic interaction of CTLA-4 with HLA-DR15 in multiple sclerosis patients. Ann Neurol 2003;54(1):119-122
31. Roxburgh RH, Sawcer S, Maranian M, et al. No evidence of a significant role for CTLA-4 in multiple sclerosis. J Neuroimmunol 2006;171(1-2):193-197
32. Fukazawa T, Kikuchi S, Miyagishi R, et al. CTLA-4 gene polymorphism is not associated with conventional multiple sclerosis in Japanese. J Neuroimmunol 2005;159(1-2):225-229
33. Teutsch SM, Booth DR, Bennetts BH, Heard RN, Stewart GJ. Association of common T cell activation gene polymorphisms with multiple sclerosis in Australian patients. J Neuroimmunol 2004;148(1-2):218-230
34. Lorentzen AR, Celius EG, Ekstrom PO, et al. Lack of association with the CD28/CTLA4/ICOS gene region among Norwegian multiple sclerosis patients. J Neuroimmunol 2005;166(1-2):197-201
35. Masterman T, Ligers A, Zhang Z, et al. CTLA4 dimorphisms and the multiple sclerosis phenotype. J Neuroimmunol 2002;131(1-2):208-212
36. Barcellos LF, Kamdar BB, Ramsay PP, et al. Clustering of autoimmune diseases in families with a high-risk for multiple sclerosis: a descriptive study [see comment]. Lancet Neurol 2006;5(11):924-931
37. Goris A, Heggarty S, Marrosu MG, et al. Linkage disequilibrium analysis of chromosome 12q14-15 in multiple sclerosis: delineation of a 118-kb interval around interferon-gamma (IFNG) that is involved in male versus female differential susceptibility. Genes Immun 2002;3(8): 470-476
38. Reboul J, Mertens C, Levillayer F, et al. Cytokines in genetic susceptibility to multiple sclerosis: a candidate gene approach. French Multiple Sclerosis Genetics Group. J Neuroimmunol 2000;102(1):107-112
39. Vandenbroeck K, Cunningham S, Goris A, et al. Polymorphisms in the interferon-gamma/interleukin-26 gene region contribute to sex bias in susceptibility to rheumatoid arthritis. Arthritis Rheum 2003;48(10):2773-2778
40. Kantarci OH, Goris A, Hebrink DD, et al. IFNG polymorphisms are associated with gender differences in susceptibility to multiple sclerosis. Genes Immun 2005;6(2):153-161
41. Dai Y, Masterman T, Huang WX, et al. Analysis of an interferon-gamma gene dinucleotide-repeat polymorphism in Nordic multiple sclerosis patients. Mult Scler 2001;7(3):157-163
42. Goris A, Epplen C, Fiten P, et al. Analysis of an IFN-gamma gene (IFNG) polymorphism in multiple sclerosis in Europe: effect of population structure on association with disease. J Interferon Cytokine Res 1999;19(9):1037-1046
43. Schrijver HM, Hooper-van Veen T, van Beizen MJ, et al. Polymorphisms in the genes encoding interferon-gamma and interferon-gamma receptors in multiple sclerosis. Eur J Immunogenet 2004;31(3):133-140
44. Bergkvist M, Olsson M, Sandberg-Wollheim M. No evidence for genetic linkage between development of multiple sclerosis and components of the IFN system and the JAK-STAT pathway. Mult Scler 2004;10(1):87-88
45. Gee JR, Keller JN. Astrocytes: regulation of brain homeostasis via apolipoprotein E. Int J Biochem Cell Biol 2005;37(6):1145-1150
46. Laskowitz DT, Horsburgh K, Roses AD. Apolipoprotein E and the CNS response to injury. J Cereb Blood Flow Metab 1998;18(5):465-471
47. Enzinger C, Ropele S, Strasser-Fuchs S, et al. Lower levels of N-acetylaspartate in multiple sclerosis patients with the apolipoprotein E epsilon4 allele [see comment]. Arch Neurol 2003;60(1):65-70
48. Schmidt S, Barcellos LF, DeSombre K, et al. Association of polymorphisms in the apolipoprotein E region with susceptibility to and progression of multiple sclerosis. Am J Hum Genet 2002;70(3):708-717
49. Kantarci OH, Hebrink DD, Achenbach SJ, et al. Association of APOE polymorphisms with disease severity in MS is limited to women [see comment]. Neurology 2004;62(5):811-814
50. Cocco E, Sotgiu A, Costa G, et al. HLA-DR, DQ_and APOE genotypes and gender influence in Sardinian primary progressive MS. Neurology 2005;64(3):564-566
51. Savettieri G, Messina D, Andreoli V, et al. Gender-related effect of clinical and genetic variables on the cognitive impairment in multiple sclerosis. J Neurol 2004;251(10):1208-1214
52. Burwick RM, Ramsay PP, Haines JL, et al. APOE epsilon variation in multiple sclerosis susceptibility and disease severity: some answers. Neurology 2006;66(9):1373-1383
53. Koutsis G, Panas M, Giogkaraki E, et al. APOE epsilon4 is associated with impaired verbal learning in patients with MS. Neurology 2007;68(8):546-549
54. Ebers GC, Kukay K, Bulman DE, et al. A full genome search in multiple sclerosis [see comment]. Nat Genet 1996;13(4):472-476
55. Zhang Z, Duvefelt K, Svensson F, et al. Two genes encoding immune-regulatory molecules (LAG3 and IL7R) confer susceptibility to multiple sclerosis. Genes Immun 2005;6(2):145-152
56. International Multiple Sclerosis Genetics Consortium, Hafler DA, Compston A, Sawcer S, et al. Risk alleles for multiple sclerosis identified by a genomewide study. N Engl J Med 2007;357(9):851-862
57. Lundmark F, Salter H, Hillert J. An association study of two functional promotor polymorphisms in the myeloperoxidase (MPO) gene in multiple sclerosis. Mult Scler 2007;13(6):697-700
58. Lucchinetti C, Bruck W, Parisi J, et al. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination [see comment]. Ann Neurol 2000;47(6):707-717
59. CHAMPS Group Study. Interferon beta-1a for optic neuritis patients at high risk for multiple sclerosis. Am J Ophthalmol 2001;132(4):463-471
60. Beck RW, Chandler DL, Cole SR, et al. Interferon beta-1a for early multiple sclerosis: CHAMPS trial subgroup analyses. Ann Neurol 2002;51(4):481-490
61. Beck RW, Trobe JD, Moke PS, et al. High- and low-risk profiles for the development of multiple sclerosis within 10 years after optic neuritis: experience of the optic neuritis treatment trial [see comment]. Arch Ophthalmol 2003;121(7):944-949
62. Cordonnier C, de Seze J, Breteau G, et al. Prospective study of patients presenting with acute partial transverse myelopathy. J Neurol 2003;250(12):1447-1452
63. Ford B, Tampieri D, Francis G. Long-term follow-up of acute partial transverse myelopathy [see comment]. Neurology 1992;42:250-252
64. Weinshenker BG, Wingerchuk DM, Vukusic S, et al. Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis. Ann Neurol 2006;59(3):566-569
65. Weinshenker BG. Plasma exchange for severe attacks of inflammatory demyelinating diseases of the central nervous system. J Clin Apher 2001;16(1):39-42
66. Keegan M, Konig F, McClelland R, et al. Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange [see comment]. Lancet 2005;366(9485):579-582
67. Wingerchuk DM. Neuromyelitis optica: current concepts. Front Biosci 2004;9:834-840
68. Kantarci O, Siva A, Eraksoy M, et al. Survival and predictors of disability in Turkish MS patients. Turkish Multiple Sclerosis Study Group (TUMSSG). Neurology 1998;51(3):765-772
69. Rodriguez M, Siva A, Ward J, et al. Impairment, disability, and handicap in multiple sclerosis: a population-based study in Olmsted County, Minnesota. Neurology 1994;44(1):28-33
70. Frohman EM, Filippi M, Stuve O, et al. Characterizing the mechanisms of progression in multiple sclerosis: evidence and new hypotheses for future directions [see comment]. Arch Neurol 2005;62(9):1345-1356
71. Runmarker B, Andersen O. Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up. Brain 1993;116(Pt 1):117-134
72. Riise T, Gronning M, Fernandez O, et al. Early prognostic factors for disability in multiple sclerosis, a European multicenter study. Acta Neurol Scand 1992;85(3):212-218
73. Confavreux C, Vukusic S, Moreau T, Adeleine P. Relapses and progression of disability in multiple sclerosis [see comment]. N Engl J Med 2000;343(20):1430-1438
74. Trojano M, Avolio C, Manzari C, et al. Multivariate analysis of predictive factors of multiple sclerosis course with a validated method to assess clinical events. J Neurol Neurosurg Psychiatry 1995;58(3):300-306
75. Bergamaschi R, Berzuini C, Romani A, Cosi V. Predicting secondary progression in relapsing-remitting multiple sclerosis: a Bayesian analysis [see comment]. J Neurol Sci 2001;189(1-2):13-21
76. Ann Marrie R, Rudick RA. Drug insight: interferon treatment in multiple sclerosis. Nat Clin Pract Neurol 2006;2(1):34-44
77. Fox EJ. Management of worsening multiple sclerosis with mitoxantrone: a review. Clin Ther 2006;28(4):461-474
78. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS). Neurology 1983;33(11):1444-1452
79. Rao SM, Leo GJ, Haughton VM, St Aubin-Faubert P, Bernardin L. Correlation of magnetic resonance imaging with neuropsychological testing in multiple sclerosis. Neurology 1989;39(2 Pt 1):161-166
80. Rudick RA. Clinical outcomes assessment in multiple sclerosis: Part I. Mult Scler 1996;2(5):244-246
81. Fischer JS, Rudick RA, Cutter GR, Reingold SC. The Multiple Sclerosis Functional Composite Measure (MSFC): an integrated approach to MS clinical outcome assessment. National MS Society Clinical Outcomes Assessment Task Force. Mult Scler 1999;5(4):244-250
82. Goodkin DE, Hertsgaard D, Seminary J. Upper extremity function in multiple sclerosis: improving assessment sensitivity with box-and-block and nine-hole peg tests. Arch Phys Med Rehabil 1988;69(10):850-854
83. Miller DM, Rudick RA, Cutter G, Baier M, Fischer JS. Clinical significance of the multiple sclerosis functional composite: relationship to patient-reported quality of life. Arch Neurol 2000;57(9):1319-1324
84. Deloire MS, Salort E, Bonnet M, et al. Cognitive impairment as marker of diffuse brain abnormalities in early relapsing remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 2005;76(4):519-526
85. Achiron A, Polliack M, Rao SM, et al. Cognitive patterns and progression in multiple sclerosis: construction and validation of percentile curves. J Neurol Neurosurg Psychiatry 2005;76(5):744-749
86. Roxburgh RHSR, Seaman SR, Mastermann T, et al. Multiple Sclerosis Severity Score. Using disability and disease duration to rate disease severity. Neurology 2005;64:1144-1151
87. Weinshenker BG, Bass B, Rice GP, et al. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain 1989;112(Pt 1):133-146
88. Weinshenker BG, Bass B, Rice GP, et al. The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course. Brain 1989;112(Pt 6):1419-1428
89. Pittock SJ, McClelland RL, Mayr WT, et al. Clinical implications of benign multiple sclerosis: a 20-year population-based follow-up study. Ann Neurol 2004;56(2):303-306
90. Pittock SJ. Does benign multiple sclerosis today imply benign multiple sclerosis tomorrow?: implications for treatment [see comment]. Neurology 2007;68:480-481
91. Langer-Gould A, Popat RA, Huang SM, et al. Clinical and demographic predictors of long-term disability in patients with relapsing-remitting multiple sclerosis: a systematic review. Arch Neurol 2006;63(12):1686-1691
92. Confavreux C, Hutchinson M, Hours MM, Cortinovis-Tourniaire P, Moreau T. Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in Multiple Sclerosis Group [see comment]. N Engl J Med 1998;339(5):285-291
93. Confavreux C, Vukusic S, Adeleine P. Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process [see comment]. Brain 2003;126(Pt 4):770-782
94. Cottrell DA, Kremenchutzky M, Rice GP, et al. The natural history of multiple sclerosis: a geographically based study. 5. The clinical features and natural history of primary progressive multiple sclerosis [see comment]. Brain 1999;122(Pt 4): 625-639
95. Tremlett H, Paty D, Devonshire V. The natural history of primary progressive MS in British Columbia, Canada. Neurology 2005;65:1919-1923
96. Sadovnick AD, Eisen K, Ebers GC, Paty DW. Cause of death in patients attending multiple sclerosis clinics [see comment]. Neurology 1991;41(8):1193-1196
97. Phadke JG. Survival pattern and cause of death in patients with multiple sclerosis: results from an epidemiological survey in north-east Scotland. J Neurol Neurosurg Psychiatry 1987;50(5):523-531
98. Riise T, Grønning M, Aarli JA, Nyland H, Larsen JP, Edland A. Prognostic factors for life expectancy in multiple sclerosis analysed by Cox-models. J Clin Epidemiol 1988;41(10):1031-1036
99. Poser S, Kurtzke JF, Poser W, Schlaf G. Survival in multiple sclerosis. J Clin Epidemiol 1989;42(2):159-168
100. Bronnum-Hansen H, Koch-Henriksen N, Hyllested K. Survival of patients with multiple sclerosis in Denmark: a nationwide, long-term epidemiologic survey. Neurology 1994;44(10):1901-1907
101. Pekmezovic T, Jarebinski M, Drulovic J, Stojsavljevic N, Levic Z. Survival of multiple sclerosis patients in the Belgrade population. Neuroepidemiology 2002;21(5):235-240
102. Wallin MT, Page WF, Kurtzke JF. Epidemiology of multiple sclerosis in US veterans. VIII. Long-term survival after onset of multiple sclerosis. Brain 2000;123(Pt 8):1677-1687